Suzhou Ribo Life Science Co., Ltd. (HKG:6938)
Hong Kong · Delayed Price · Currency is HKD 51.05
+1.05 (2.10%)
Jul 3, 2026, 4:08 PM HKT
Suzhou Ribo Life Science Revenue
In the year 2025, Suzhou Ribo Life Science had annual revenue of 148.51M CNY with 4.12% growth. Suzhou Ribo Life Science had revenue of 44.70M in the half year ending December 31, 2025.
Revenue
148.51M CNY
Revenue Growth
+4.12%
P/S Ratio
52.68
Revenue / Employee
364.89K CNY
Employees
407
Market Cap
8.71B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 148.51M | 5.88M | 4.12% |
| Dec 31, 2024 | 142.63M | 142.58M | 324,052.27% |
| Dec 31, 2023 | 44.00K | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Haohai Biological Technology | 2.73B |
| Everest Medicines | 1.90B |
| HBM Holdings | 1.23B |
| Lepu Biopharma | 1.04B |
| Abbisko Cayman | 681.17M |
| Alphamab Oncology | 630.11M |
| CStone Pharmaceuticals | 299.99M |
| Nanjing Leads Biolabs | 197.25M |
Suzhou Ribo Life Science News
- 3 months ago - Suzhou Ribo Life Science Earnings release: H2 2025 - Filings
- 3 months ago - Suzhou Ribo Life Science Annual report: H2 2025 - Filings